The SOL-1 Phase 3 superiority data is the key catalyst to watch at CTS 2026 (June 12-13). Positive efficacy or safety differentiation could drive upside given the 94% bullish analyst consensus and the early-stage biotech stage of Ocular. The HELIOS program update in NPDR may expand the addressable market thesis. Expect high volatility around the conference dates; traders should position ahead of the presentation if prior trial signals were favorable, but note the historical T+20 win rate on OCUL reports is only 30% with negative average alpha.
Price Chart
Executive Summary
Ocular Therapeutix announced its participation at Clinical Trials at the Summit 2026, where it will present multiple data updates on AXPAXLI (OTX-TKI) including results from the SOL-1 Phase 3 superiority trial in wet AMD and a HELIOS program update in NPDR. The conference presentations are scheduled for June 12-13, 2026, in Las Vegas, with a CEO fireside chat and several clinical sessions.
Key Facts
- SOL-1 Phase 3 superiority trial efficacy outcomes with OTX-TKI in neovascular AMD to be presented at CTS 2026 on June 13
- HELIOS program update on OTX-TKI in nonproliferative diabetic retinopathy (NPDR) also scheduled for June 13
- Safety and tolerability profile of OTX-TKI in neovascular AMD presented separately on the same day
- Pravin U. Dugel, MD (CEO) participating in fireside chat 'From Global KOL to CEO' and panel 'From Innovation to Approval'
- AXPAXLI (OTX-TKI) is an axitinib intravitreal hydrogel based on ELUTYX bioresorbable hydrogel technology, currently in Phase 3 for wet AMD and diabetic retinal disease
Financial Impact
No financial data disclosed; presentations focus on clinical trial results for AXPAXLI. Positive SOL-1 data could support regulatory filings and enhance pipeline value for a $1.8B market cap biotech.
Risk Factors
- SOL-1 Phase 3 data may fail to show superiority vs. existing anti-VEGF standard of care
- Competitive pressure from faricimab and other long-acting agents in wet AMD
- History of substantial negative alpha at T+20 (avg -8.41%) on Ocular reports despite positive near-term moves
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306630 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | Insider Cluster | $10.90 $7.67 | ▼ −29.63% | ▼ −29.30% | $6.96 (−36.15%) |
Aug 26, 2026 5w ago | Insider Cluster | $10.82 $9.82 | ▼ −9.24% | ▼ −8.73% | $6.96 (−35.67%) |
Aug 3, 2026 8w ago | 8-K | $8.40 $10.49 | ▲ +24.88% | ▲ +23.64% | $6.96 (−17.14%) |
Jun 17, 2026 15w ago | Press Release | $9.64 $9.17 | ▼ −4.93% | ▼ −6.24% | $6.96 (−27.80%) |
Jun 12, 2026 16w ago | 8-K | $8.99 $9.88 | ▲ +9.90% | ▲ +10.65% | $6.96 (−22.58%) |
Jun 4, 2026 17w ago | Press Release | $8.80 $9.64 | ▲ +9.55% | ▲ +10.92% | $6.96 (−20.91%) |
May 28, 2026 18w ago | Insider Cluster | $9.01 $9.90 | ▲ +9.88% | ▲ +11.67% | $6.96 (−22.75%) |
May 5, 2026 21w ago | 8-K | $9.71 $8.31 | ▼ −14.42% | ▼ −19.37% | $6.96 (−28.32%) |
May 5, 2026 21w ago | Press Release | $9.71 $8.31 | ▼ −14.42% | ▼ −19.37% | $6.96 (−28.32%) |
Apr 30, 2026 22w ago | DEFA14A | $9.43 $8.93 | ▼ −5.30% | ▼ −10.57% | $6.96 (−26.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access